Equities research analysts expect Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to report earnings of ($1.01) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Merrimack Pharmaceuticals’ earnings. Merrimack Pharmaceuticals posted earnings of ($0.89) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 13.5%. The firm is expected to issue its next quarterly earnings report on Monday, March 11th.

On average, analysts expect that Merrimack Pharmaceuticals will report full year earnings of ($4.60) per share for the current fiscal year. For the next financial year, analysts anticipate that the company will post earnings of ($2.88) per share, with EPS estimates ranging from ($3.59) to ($2.16). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals (NASDAQ:MACK) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.65).

A number of equities research analysts recently issued reports on MACK shares. Robert W. Baird set a $4.00 price objective on Merrimack Pharmaceuticals and gave the stock a “hold” rating in a research report on Saturday, October 20th. Cowen reiterated a “hold” rating on shares of Merrimack Pharmaceuticals in a research report on Friday, October 19th. ValuEngine upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. Finally, Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Wednesday, October 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Merrimack Pharmaceuticals has an average rating of “Hold” and an average price target of $4.38.

Several hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd raised its position in Merrimack Pharmaceuticals by 122.9% during the second quarter. Dynamic Technology Lab Private Ltd now owns 22,731 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 12,534 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Merrimack Pharmaceuticals during the second quarter valued at about $143,000. Stonebridge Capital Management Inc. raised its position in Merrimack Pharmaceuticals by 64.7% during the third quarter. Stonebridge Capital Management Inc. now owns 34,130 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 13,405 shares in the last quarter. LMR Partners LLP purchased a new stake in Merrimack Pharmaceuticals during the second quarter valued at about $211,000. Finally, Clearline Capital LP purchased a new stake in Merrimack Pharmaceuticals during the second quarter valued at about $291,000. Institutional investors own 47.33% of the company’s stock.

Shares of MACK stock remained flat at $$4.54 on Wednesday. The company had a trading volume of 25,312 shares, compared to its average volume of 146,899. The company has a quick ratio of 3.96, a current ratio of 3.96 and a debt-to-equity ratio of 0.22. Merrimack Pharmaceuticals has a one year low of $3.34 and a one year high of $12.45. The stock has a market capitalization of $60.18 million, a P/E ratio of -0.80 and a beta of 2.56.

Merrimack Pharmaceuticals Company Profile

Merrimack Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.

Recommended Story: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Merrimack Pharmaceuticals (MACK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.